Centocor Remicade
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
nfliximab receives supplemental approval Dec. 29 for use in combination with methotrexate to inhibit "the progression of structural damage in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate." The agent was previously approved for use with methotrexate to reduce signs and symptoms of RA. For the new indication, Centocor has a Phase IV commitment to conduct a 1,000-patient study on the effects of infliximab on infections. The study, which is expected to begin in September, will assess the standard 3 mg/kg dose and a new 10 mg/kg dose that labeling says may be considered for patients with incomplete responses. A final study report is expected in September 200
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.